| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.04. | INVENTIVA: Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F | 240 | GlobeNewswire (Europe) | Daix (France), Long Island City (New York, United States), April 3, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 03.04. | Inventiva S.A. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 01.04. | Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript | 3 | Insider Monkey | ||
| 28.03. | INVENTIVA: Inventiva announces the nomination of Andre Turenne as Director | 289 | GlobeNewswire (Europe) | Daix (France), Long Island City (New York, United States), March 28, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 27.03. | Inventiva S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.03. | Inventiva GAAP EPS of -€2.43, revenue of €17.48M | 1 | Seeking Alpha | ||
| 27.03. | INVENTIVA: Inventiva reports its 2023 full-year results | 333 | GlobeNewswire (Europe) | Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million1, and long-term deposit... ► Artikel lesen | |
| 22.03. | INVENTIVA: Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results | 310 | GlobeNewswire (Europe) | Daix (France), Long Island City (New York, United States), March 22, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral... ► Artikel lesen | |
| 18.03. | Inventiva Phase 2 study for MASH drug meets primary endpoint | 4 | Seeking Alpha | ||
| 18.03. | Inventiva S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 18.03. | INVENTIVA: Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D | 258 | GlobeNewswire (Europe) | LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.Statistical significance... ► Artikel lesen | |
| 13.03. | INVENTIVA: Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D | 301 | GlobeNewswire (Europe) | Daix (France), Long Island City (New York, United States), March 13, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 08.03. | Inventiva resumes Phase 3 study for NASH drug, stock up 6% | 2 | Seeking Alpha | ||
| 07.03. | Inventiva S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 16.02. | Inventiva drops after adverse event in Phase 3 trial for NASH drug | 6 | Seeking Alpha | ||
| 16.02. | Why Is Liver Disease-Focused Inventiva Stock Trading Lower Today? | 1 | Benzinga.com | ||
| 16.02. | Inventiva pauses phase 3 MASH study over patient's raised liver enzymes | 6 | FierceBiotech | ||
| 15.02. | Inventiva S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.02. | INVENTIVA: Inventiva reports preliminary 2023 fiscal year financial Information and provides an update on its clinical trial NATiV3 | 543 | GlobeNewswire (Europe) | Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022Cash and cash equivalents at €26.9 million, short-term deposits at € 0.01 million2, and long-term deposit at €9.0... ► Artikel lesen | |
| 24.01. | INVENTIVA: Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux | 673 | GlobeNewswire (Europe) | Daix (France), Long Island City (New York, United States), January 24, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 444 |
| BAYER | 287 |
| BYD | 256 |
| NEL | 239 |
| NVIDIA | 235 |
| PLUG POWER | 204 |
| TESLA | 200 |
| TUI | 199 |
| DEUTSCHE BANK | 195 |
| SUPER MICRO COMPUTER | 195 |
| APPLE | 190 |
| RHEINMETALL | 168 |
| AMAZON | 158 |
| MERCEDES-BENZ | 155 |
| RWE | 155 |
| DEUTSCHE LUFTHANSA | 152 |
| BERKSHIRE HATHAWAY | 136 |
| COMMERZBANK | 124 |
| BIONTECH | 121 |
| PAYPAL | 121 |
| AIXTRON SE | 120 |
| RENK GROUP | 120 |
| ALLIANZ | 119 |
| VOLKSWAGEN | 116 |
| BASF | 113 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
